Impiego degli Inibitori della Pompa protonica (IPP) in Piemonte: indagine sulle abitudini prescrittive dei Medici di Medicina Generale

Impiego degli Inibitori della Pompa protonica (IPP) in Piemonte: indagine sulle abitudini prescrittive dei Medici di Medicina Generale

Authors

  • Adriana Ceci Consorzio per le Valutazioni Biologiche e Farmacologiche (Università degli Studi di Pavia - Fondazione Salvatore Maugeri)

  • Paola Baiardi Consorzio per le Valutazioni Biologiche e Farmacologiche (Università degli Studi di Pavia - Fondazione Salvatore Maugeri)

  • Simona Ravera Consorzio per le Valutazioni Biologiche e Farmacologiche (Università degli Studi di Pavia - Fondazione Salvatore Maugeri)

  • Emilia Chiò Regione Piemonte – Direzione Controllo delle Attività Sanitarie, Settore Assistenza Farmaceutica

  • Pellegri Cristiana Regione Piemonte – Direzione Controllo delle Attività Sanitarie, Settore Assistenza Farmaceutica

  • Cristina Negrini Pbe Consulting

  • Giorgio Capitelli Federazione Italiana Medici Pediatri (FIMP)

  • Renato Cela Federazione Medici

  • Giuliana Corda Sindacato Nazionale Autonomo Medici Italiani (SNAMI)

  • Ezio Gaia Azienda Ospedaliera S. Luigi di Orbassano

  • Sandro Gozzi Federfarma Piemonte

  • Francesco Marocchino Federazione Italiana Medici di Medicina Generale (FIMMG)

  • Eleonora Marrazzo Centro regionale di documentazione sul farmaco

  • Andrea Pizzini Federazione Italiana Medici di Medicina Generale (FIMMG)

  • Aldo Ravaglia Pediatra di libera scelta

  • Franco Saullo Sindacato Italiano Medici del Territorio (SIMET)

  • Marcello Tonini Dipartimento di Scienze Fisiologiche Farmacologiche Cellulari Molecolari Università degli Studi di Pavia



DOI:

https://doi.org/10.7175/fe.v5i2.791

Abstract

Proton Pump Inhibitors (PPIs) (Omeprazole, Lansoprazole, Pantoprazole, Rabeprazole and Esomeprazole), one of the most commonly prescribed classes of medications in the primary care setting, are considered a major advance in the treatment of acid-peptic diseases. In Italy PPIs are reimbursed by National Health Service on the basis of CUF (Commissione Unica del Farmaco) 1 and 48 Notes. In 2002 and 2003 a significant increase in PPIs consumption and expenditure have been documented, showing differences between regions. The aim of this study is to investigate and monitor, at regional level, type and entity of PPIs use through a drug utilization study, evaluating prescribing behaviour and compliance of PPIs treatments with CUF Notes indications. The study has been carried out on a sample of 436 General Practitioners belonging to 22 Piemonte’s ASL (Aziende Sanitarie Locali). The data analysis shows that acid-related pathologies are significantly more common in patients with at least 50 years of age and the most frequent condition is represented by gastroesophageal reflux disease. Despite the general conditions of PPIs use by General Practitioners in terms of duration and dosage of therapy result in most cases (from 49% to 80% for duration and from 54% to 97% for dosage) compliant with what proposed by CUF Notes, in some cases the same CUF Notes indications seem to be not observed. Consequently the Piemonte Region has decided to plan a guideline on PPIs rational use. Such guideline, expected to be introduced in the regional area, may also be considered as an instrument able to lead to a more appropriate expenditure for this drug class. Moreover, in order to control PPIs expenditure, pharmacoeconomic methodologies can be applied allowing to identify the most cost - effective active substance and therapeutic scheme, overcoming CUF Notes which consider all PPIs use under the same reimbursement conditions.

Downloads

Published

2004-06-15

How to Cite

Ceci, A., Baiardi, P., Ravera, S., Chiò, E., Cristiana, P., Negrini, C., … Tonini, M. (2004). Impiego degli Inibitori della Pompa protonica (IPP) in Piemonte: indagine sulle abitudini prescrittive dei Medici di Medicina Generale. Farmeconomia. Health Economics and Therapeutic Pathways, 5(2), 103–115. https://doi.org/10.7175/fe.v5i2.791

Issue

Vol. 5 No. 2 (2004)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
  4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)